Skip to main navigation Skip to search Skip to main content

Is episialin/MUC1 involved in breast cancer progression?

  • J. Hilkens
  • , H. L. Vos
  • , J. Wesseling
  • , M. Boer
  • , J. Storm
  • , S. van der Valk
  • , J. Calafat
  • , C. Patriarca
  • Netherlands Cancer Institute
  • The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands

Research output: Contribution to journalArticlepeer-review

72 Citations (Scopus)

Abstract

Episialin, also designated MUC1, CA 15-3 antigen and PEM, is an established serum marker for breast cancer. Its function and possible involvement in tumor progression has not yet been completely established. The molecule is an extended rod-like molecule protruding high above the cell surface. It is often highly overexpressed in breast cancer relative to normal breast epithelium cells. Overexpression of episialin on cells in vitro reduces cell-cell and cellextracellular matrix adhesion, because the rod-like molecule masks the adhesion receptors. Episialin also exerts its antiadhesion effect in vivo. In certain human tumors, where episialin was present at the basal side of the cell, abnormal contacts between the plasma membrane and the stroma were observed. As a consequence of its anti-adhesion properties, episialin overexpression reduces the sensitivity of the cells for cytotoxic lymphocytes. This might be one of the reasons why episialin transfected cells are more potent to form experimental metastases after i.v. injection into nude mice.

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalCancer Letters
Volume90
Issue number1
DOIs
Publication statusPublished - 23 Mar 1995
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Adhesion
  • Breast cancer
  • Cytotoxic lymphocytes
  • Episialin
  • Metastasis

Fingerprint

Dive into the research topics of 'Is episialin/MUC1 involved in breast cancer progression?'. Together they form a unique fingerprint.

Cite this